Why Body Surface Area Alone Doesn't Capture Vitiligo Severity

This episode, "Why Body Surface Area Alone Doesn't Capture Vitiligo Severity," features Dr. Lal and Dr. Rosmarin examining why body surface area alone can fall short as a marker of disease severity.

Dr. Lal opens by cautioning against over-generalizing body surface area data, noting that most vitiligo patients have between eight and fifteen percent involvement, with roughly eighty-five percent affected at less than ten percent. Even ten percent, he explains, can look substantial depending on location, since the face, neck, and head alone can account for a large share of that total. He describes body surface area as a useful count of how many regions are involved, but says real concern begins once involvement approaches thirty percent, a threshold that changes the entire long-term treatment strategy. Below ten percent, topical therapy remains feasible; beyond it, phototherapy and more aggressive options become necessary.

Dr. Lal adds that vitiligo carries no physical symptoms, so clinicians instead watch for phenotypic markers of activity, including trichrome vitiligo, confetti vitiligo, and koebnerization, which often predict a worse prognosis and shift treatment discussions more than surface area alone. Location matters too: facial, hand, and segmental versus non-segmental presentations each carry different implications. He emphasizes catching segmental disease within its first three months to give patients the best chance at effective early treatment.

Dr. Rosmarin agrees, describing body surface area as an objective measure of extent that fails to capture subjective severity. A small patch in a highly visible or sensitive location can be more severe, in his view, than a larger area the patient barely notices. Because severity in vitiligo is so tied to the patient's own experience, he argues it resists the kind of clean quantification that other dermatologic conditions allow, complicating any effort to standardize urgency purely around percentage of skin involved.

Up next, in "Payer Barriers and Anatomic Urgency in Vitiligo Treatment," the panel turns to the payer barriers that can delay treatment and the anatomic clues that signal urgency.